Koo Jakap's Form 4 filing
Apimeds Pharmaceuticals US, Inc. (APUS) · filed May 14, 2025
- Accession no.
- 0001474506-25-000090
- Filed
- May 14, 2025
- Trade date
- May 12, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $56.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Koo JakapCIK 0002041972 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. The reporting person undertakes to provide to Apimeds Pharmaceuticals US, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
These shares were sold in multiple transactions at prices ranging from $1.9774 to $2.2000, inclusive.
Referenced by the price of 1 transaction in Table I.